Evidence map›Paper›PMID 42883858›Full record

ArticleInternational journal of molecular sciences2026

Immunohistochemical Classification and Prognostic Significance of Germinal Center-like and Memory Cell-like Subtypes of Follicular Lymphoma Using FOXP1, LMO2, CD22, and MUM1.

Tülay Koç, Sedanur Aydın, Zeynep Öztürk, Hatice Terzi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tülay KoçDepartment of Pathology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas 58140, Türkiye.ORCID 0000-0001-8612-0238
Sedanur AydınDepartment of Pathology, Sivas Numune Hospital, Sivas 58140, Türkiye.
Zeynep ÖztürkDepartment of Pathology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas 58140, Türkiye.ORCID 0009-0003-8690-494X
Hatice TerziDepartment of Hematology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas 58140, Türkiye.ORCID 0000-0003-3471-1305

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Follicular lymphoma (FL) is an indolent B-cell lymphoma with considerable biological and clinical heterogeneity, highlighting the need for additional prognostic biomarkers beyond conventional clinicopathological parameters. This study aimed to evaluate the prognostic significance of an immunohistochemical classification separating FL into a germinal center-like (GC-like) phenotype, characterized by retention of germinal-center-associated features, and a memory-like (Mem-like) phenotype, reflecting a more differentiated post-germinal-center/memory B-cell state. Fifty-one patients with FL were retrospectively analyzed for clinicopathological characteristics, immunohistochemical findings, relapse, and overall survival (OS). LMO2 expression was detected in 70.6% of cases and was associated with lower mortality (19.4% vs. 60.0%,

Indexed as

Adaptor Proteins, Signal TransducingForkhead Transcription FactorsGerminal CenterLIM Domain ProteinsLymphoma, FollicularProto-Oncogene ProteinsRepressor ProteinsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansImmunohistochemistryInterferon Regulatory Factor-4MaleAdaptor Proteins, Signal TransducingBiomarkers, TumorForkhead Transcription FactorsFOXP1 protein, humanInterferon Regulatory Factor-4LIM Domain ProteinsLMO2 protein, humanProto-Oncogene ProteinsRepressor Proteinsfollicular lymphomaFOXP1germinal center-like subtypeimmunohistochemistryLMO2memory-like subtypeoverall survivalprognosis

Identifiers

PMID42883858
PMCPMC13665123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.